BioWorld Asia

Oct. 1, 2008

Nitec Pharma Gets $22M to Fund Lodotra Launch

With a first European approval for its rheumatoid arthritis drug Lodotra imminent, Nitec Pharma AG raised CHF24 million (US$22 million) in a private equity round led by Munich, Germany-based TVM Capital. (BioWorld International) Read More

Telormedix Gets $19M in Series A Round

Elucidation of Cancer Growth Yields Potential Drug Targets

Nextech Closes Oncology Fund with $65M in Hand

Phynova Focusing on China, Pipeline and Conserving Cash

Genetically Modified Cotton is Good Neighbor to Other Crops

NicOx Signs Naproxcinod Agreement with Capsugel

ExonHit Therapeutics to Provide Genomic Services to French CRO

FDA Investigating Deaths in Ortho's German Stroke Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 27, 2026.

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...